Korean Biopharma Financings Remain In Doldrums But Recovery In Sight?
US Lazertinib Decision A Catalyst
As investor sentiment around Korean biopharma IPOs and financings remained tepid in the second quarter, companies turned to other ways of raising money, including rights offerings. But there are signs of recovery and upcoming catalysts, while on the M&A front Boryung divested a vaccine subsidiary to a private equity consortium.
